When was Kriya Therapeutics founded?

Kriya Therapeutics was founded in 2012 and raised its 1st funding round 7 years after it was founded.

Where is Kriya Therapeutics located?

Kriya Therapeutics is headquartered in Redwood City, United States. It is registered at Puducherry · City in Union Territory Of Puducherry, India.

Who is the current CEO of Kriya Therapeutics?

Shankar Ramaswamy of Kriya Therapeutics. They have also founded 1 company.

How many employees does Kriya Therapeutics have?

As of Mar 01, 2026, the latest employee count at Kriya Therapeutics is 10 - 49.

Is Kriya Therapeutics a funded company?

Kriya Therapeutics is a funded company, having raised a total of $938M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2019.

How much is Kriya Therapeutics worth?

The latest valuation of Kriya Therapeutics is $***** as of Jul 01, 2025.

When was the latest funding round of Kriya Therapeutics?

Kriya Therapeutics' latest funding was a $***** Series D round on Jul 31, 2025, with participation from 5 investors.

Where does Kriya Therapeutics rank among its competitors?

Kriya Therapeutics ranks 110th amongst 3902 active competitors, of which 1343 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kriya Therapeutics?

Kriya Therapeutics' top competitors include Jazz Pharmaceuticals, Alnylam and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kriya Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.

Website: kriyatherapeutics.com
Social
Registered Address: Puducherry · City in Union Territory Of Puducherry, India

Key Metrics

Founded Year

2012

Location

Redwood City, United States

Stage

Series D

Total Funding

$938M in 5 rounds

Latest Funding Round

Series D, Jul 31, 2025, $*****

Post Money Valuation

$***** as on Jul 01, 2025

Investors

Patient Square Capital & 17 more

Ranked

110^th among 3902 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Investment & Acquisitions

Tramontane Therapeutics & 1 more

Similar Companies

Jazz Pharmaceuticals & 1981 more

View Kriya Therapeutics' full profile

Kriya Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Kriya Therapeutics Inc. CIN: 843432780 , United States, Active	Dec 31, 2011	-	179 (As on Dec 31, 2024)	-

Kriya Therapeutics has raised a total funding of $938M over 5 rounds. Its first funding round was on 2019. Its latest funding round was a Series D round on Jul 31, 2025 for $*****. 5 investors participated in its latest round. Kriya Therapeutics has 16 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Kriya Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 31, 2025	6278648	Series D	7007973	7358018	2349200	4989321
May 10, 2022	3591245	Series C	7918874	4260897	7058177	Bluebird Ventures & 8 more
Jun 30, 2021	5937367	Series B	6733307	1992238	Patient Square Capital	Woodline Partners & 11 more

Access funding benchmarks and valuations. Sign up today!

View details of Kriya Therapeutics's funding rounds and investors

The founders of Kriya Therapeutics are Shankar Ramaswamy and Roger Jeffs. Shankar Ramaswamy is the CEO of Kriya Therapeutics.

Here are the details of Kriya Therapeutics' key team members:

Shankar Ramaswamy: Co-Founder & CEO of Kriya Therapeutics.
Roger Jeffs: Co-Founder of Kriya Therapeutics.

View details of Kriya Therapeutics's Founder profiles and Board Members

Kriya Therapeutics' employee count trend

Kriya Therapeutics has 10 - 49 employees as of Mar 26. Here is Kriya Therapeutics's employee count trend over the years:

Employee count trend for Kriya Therapeutics

Uncover Kriya Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kriya Therapeutics include Jazz Pharmaceuticals, Alnylam and Biogen. Here is the list of Top 10 competitors of Kriya Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
110th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Foresite Capital, CAM Capital & 16 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Kriya Therapeutics's competitors? Click here to see the top ones

Kriya Therapeutics has acquired 2 companies including Tramontane Therapeutics and Redpin Therapeutics. Kriya Therapeutics has not made any investments as of now.

Here is the latest report on Kriya Therapeutics's sector: